GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against cancers and infectious diseases, announced relocations of its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area. The moves, scheduled for fourth quarter of 2025, will support GeoVax's continued growth, expanding pipeline, and preparation for product commercialization.
GeoVax's laboratory group is relocating to Science Square / Portal Innovations, located in midtown Atlanta. This state-of-the-art facility will provide the Company's R&D team with expanded access to modern laboratories and collaborative research environments designed to accelerate innovation and development activities. The Company's new corporate headquarters will be located at 1955 Lake Park Drive in Smyrna, Georgia, establishing a new hub for corporate operations and leadership activities.
These relocations strengthen GeoVax's ties to Georgia's bio-ecosystem and position the company for late-stage development and market readiness. The strategic moves come at a critical time as the company advances multiple clinical programs, including its promising GEO-MVA program and clinical trials in cancer therapy and infectious disease vaccines.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that these moves reflect a significant milestone in GeoVax's evolution. By placing members of the R&D team in one of the most dynamic bio-research ecosystems in the Southeast, and by expanding the administrative base, GeoVax is positioning itself for an accelerated next stage of growth. These facilities will support the company's broad and advancing pipeline.
The relocation to Portal Atlanta at Science Square Labs represents a strategic alignment with innovation infrastructure. Eddie Lai, Director of Business Development at Atlanta Portal Innovations, noted that GeoVax brings a strong legacy of innovation rooted in the Southeast to the Portal Innovations ecosystem that includes 100+ innovative companies utilizing sites across the country. As an innovation engine, Portal Innovations supports scientific companies including life sciences and biotech in all stages of development in both R&D and administrative capabilities.
The relocations underscore GeoVax's trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities. As the Company builds momentum with a deepening pipeline and strategic partnerships, its enhanced infrastructure will provide a strong foundation to meet global healthcare needs. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.
This development matters because it represents a significant investment in biotechnology infrastructure that could accelerate the development of critical medical treatments. The expansion positions GeoVax to advance multiple clinical programs simultaneously, including their next-generation COVID-19 vaccine currently in three Phase 2 clinical trials and their novel oncolytic solid tumor gene-directed therapy, Gedeptin®, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
The company is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. This accelerated development pathway could bring important public health tools to market more quickly, addressing ongoing global health challenges. The enhanced research capabilities and collaborative environment provided by the new facilities may enable faster innovation cycles and more efficient development of these critical medical interventions.
